-
-
-
-
-
-
-
Celldex reports sustained angioedema improvements 7 months post-treatment
-
-
-
-
-
-
-
Celldex Therapeutics (CLDX) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Increasing unusual call option volume: CDLX INFY VLY REKR LDI AQST UP BFLY
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX)
-
-
-
-
-
-
-
Celldex (CLDX) Tops Q1 EPS by 3c
-
-
-
-
-
-
-
Stifel on Celldex (CLDX) and Third Harmonic Bio (THRD): 'we continue to like the prospects of CLDX and THRD as both first-in-class and an oral pure-play'
-
-
-
-
-
-
-
Citi Starts Celldex Therapeutics (CLDX) at Buy
-
450,263 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

